Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Tumor Lysis Syndrome 1Hematologic Neoplasms 1

Interventions

Cyclophosphamide 15fludarabine 12Mycophenolic Acid 10Standard of Care 9venetoclax 7Whole-Body Irradiation 7Tacrolimus 7Specimen Handling 7Sirolimus 6Practice Guidelines as Topic 6trametinib 5Melphalan 5Azacitidine 5fludarabine phosphate 4Mesna 4Magnetic Resonance Spectroscopy 4Filgrastim 4Biopsy 4Behavior Therapy 4Thiotepa 3Surveys and Questionnaires 3Radiosurgery 3Peripheral Blood Stem Cell Transplantation 3Interviews as Topic 3GSK2636771 3Educational Status 3Cytarabine 3Crizotinib 3Busulfan 3thymoglobulin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hematologic Neoplasms × Pegloticase × 90 days × Clear all
NCT04745910 2026-05-06

Pegloticase for the Reduction of Uric Acid in Patients With Tumor Lysis Syndrome

M.D. Anderson Cancer Center

Phase 4 Completed
10 enrolled
Other hematologic neoplasm

Tumor Lysis Syndrome, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡